Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo

Vascular Pharmacology

Volumn 56, Issue 1-2, 2012, Pages 47-55

  Muto, Akihito ^a   Panitch, Alyssa ^c   Kim, Namho ^c   Park, Kinam ^c   Komalavilas, Padmini ^d,e   Brophy, Colleen M ^d,e   Dardik, Alan ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c PURDUE UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Intimal hyperplasia; MAPKAP kinase II; MMI 0100; Signal transduction; Vein graft

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE II; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MMI 0100; NITROPRUSSIDE SODIUM; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; FIBROSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VEIN GRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROSIS; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; INTERLEUKIN-6; INTERLEUKIN-8; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR SEQUENCE DATA; MYOCYTES, SMOOTH MUSCLE; NITROPRUSSIDE; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SAPHENOUS VEIN; TUNICA INTIMA; VASODILATION;

EID: 84856245312     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.07.008     Document Type: Article

References (42)

1. Ackah E., Yu J., Zoellner S., Iwakiri Y., Skurk C., Shibata R., Ouchi N., Easton R.M., Galasso G., Birnbaum M.J., Walsh K., Sessa W.C. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Investig. 2005, 115(8):2119-2127. Aug.
2. Alexander J.H., Hafley G., Harrington R.A., Peterson E.D., Ferguson T.B., Lorenz T.J., Goyal A., Gibson M., Mack M.J., Gennevois D., Califf R.M., Kouchoukos N.T. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005, 294(19):2446-2454. PREVENT IV Investigators.
3. Allaire E., Clowes A.W. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann. Thorac. Surg. 1997, 63(2):582-591. Feb.
4. Clowes A.W., Reidy M.A. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia - a review. J. Vasc. Surg. 1991, 13(6):885-891. Jun.
5. Conte M.S., Bandyk D.F., Clowes A.W., Moneta G.L., Seely L., Lorenz T.J., Namini H., Hamdan A.D., Roddy S.P., Belkin M., Berceli S.A., DeMasi R.J., Samson R.H., Berman S.S. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 2006, 43(4):742-751. PREVENT III Investigators.
6. Coxon P.Y., Rane M.J., Uriarte S., Powell D.W., Singh S., Butt W., Chen Q., McLeish K.R. MAPK-activated protein kinase-2 participates in p38 MAPK-dependent and ERK-dependent functions in human neutrophils. Cell. Signal. 2003, 15(11):993-1001. Nov.
7. Danenberg H.D., Fishbein I., Gao J.C., Monkkonen J., Reich R., Gati I., Moerman E., Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002, 106(5):599-605.
8. Dashwood M.R., Loesch A. Surgical damage of the saphenous vein and graft patency. J. Thorac. Cardiovasc. Surg. 2007, 133(1):274-275. Jan.
9. Dashwood M., Anand R., Loesch A., Souza D. Surgical trauma and vein graft failure: further evidence for a role of ET-1 in graft occlusion. J. Cardiovasc. Pharmacol. 2004, 44(Suppl 1):S16-S19. Nov.
10. Donovan M.J., Miranda R.C., Kraemer R., McCaffrey T.A., Tessarollo L., Mahadeo D., Sharif S., Kaplan D.R., Tsoulfas P., Parada L., Toran-Allerand C.D., Hajjar D.P., Hempstead B.L. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am. J. Pathol. 1995, 147(2):309-324. Aug.
11. Epstein H., Grad E., Golomb M., Koroukhov N., Edelman E.R., Golomb G., Danenberg H.D. Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis 2008, 199(1):41-46. Jul.
12. Funding A.T., Johansen C., Gaestel M., Bibby B.M., Lilleholt L.L., Kragballe K., Iversen L. Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J Invest Dermatol. 2009, 129(4):891-898. Apr.
13. Hagood J.S., Olman M.A. Muscle fatigue: MK2 signaling and myofibroblast differentiation. Am. J. Respir. Cell Mol. Biol. 2007, 37(5):503-506. Nov.
14. Hayess K., Benndorf R. Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem. Pharmacol. 1997, 53(9):1239-1247. May 9.
15. Kavalukas S.L., et al. MK2 inhibitor peptide reduces adhesion formation without affecting colonic anastomotic healing. J. Am. Coll. Surg. 2009, 209(3). p. S17-S17.
16. Kent K.C., Liu B. Intimal hyperplasia - still here after all these years!. Ann. Vasc. Surg. 2004, 18(2):135-137. Mar.
17. Klyachkin M.L., Davies M.G., Svendsen E., Kim J.H., Massey M.F., Barber L., McCann R.L., Hagen P.O. Hypercholesterolemia and experimental vein grafts: accelerated development of intimal hyperplasia and an increase in abnormal vasomotor function. J. Surg. Res. 1993, 54(5):451-468. May.
18. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1999, 1(2):94-97. Jun.
19. Kotlyarov A., Yannoni Y., Fritz S., Laass K., Telliez J.B., Pitman D., Lin L.L., Gaestel M. Distinct cellular functions of MK2. Mol. Cell. Biol. 2002, 22(13):4827-4835. Jul.
20. Kritz A.B., Yu J., Wright P.L., Wan S., George S.J., Halliday C., Kang N., Sessa W.C., Baker A.H. In vivo modulation of Nogo-B attenuates neointima formation. Mol. Ther. 2008, 16(11):1798-1804. Nov.
21. Lehner M.D., Schwoebel F., Kotlyarov A., Leist M., Gaestel M., Hartung T. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J. Immunol. 2002, 168(9):4667-4673. May 1.
22. LoGerfo F.W., Quist W.C., Cantelmo N.L., Haudenschild C.C. Integrity of vein grafts as a function of initial intimal and medial preservation. Circulation 1983, 68(3 Pt 2):II117-II124. Sep.
23. Lopes L.B., Flynn C., Komalavilas P., Panitch A., Brophy C.M., Seal B.L. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Biochem. Biophys. Res. Commun. 2009, 382(3):535-539. May 8.
24. Lorusso R., De Cicco G., Beghi C., Gherli T., Poli E., Corradi D., Maestri R., Bonadonna S., Mancini T., Giustina A. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Int. J. Cardiol. 2007, 118(2):164-169. May 31.
25. Mahtani K.R., Brook M., Dean J.L.E., Sully G., Saklatvala J., Clark A. Mitogen-Activated Protein Kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of Tumor Necrosis Factor Alpha mRNA stability. Mol. Cell. Biol. 2001, 21(19):6461-6469. October.
26. Mosse P.R., Campbell G.R., Wang Z.L., Campbell J.H. Smooth muscle phenotypic expression in human carotid arteries. I. Comparison of cells from diffuse intimal thickenings adjacent to atheromatous plaques with those of the media. Lab. Investig. 1985, 53(5):556-562. Nov.
27. Motwani J.G., Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97(9):916-931. Mar 10.
28. Muto A., Yi T., Harrison K.D., Dávalos A., Fancher T.T., Ziegler K.R., Feigel A., Kondo Y., Nishibe T., Sessa W.C., Dardik A. Eph-B4 prevents venous adaptive remodeling in the adult arterial environment. J. Exp. Med. 2011, 208(3):561-575.
29. Neininger A., Kontoyiannis D., Kotlyarov A., Winzen R., Eckert R., Volk H.D., Holtmann H., Kollias G., Gaestel M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 2002, 277(5):3065-3068. Feb 1.
30. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., Overbeek P., Richardson J.A., Grant S.R., Olson E.N. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 2000, 105(10):1395-1406. May.
31. Rouse J., Cohen P., Trigon S., Morange M., Alonso-Llamazares A., Zamanillo D., Hunt T., Nebreda A.R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994, 78(6):1027-1037. Sep 23.
32. Rousseau S., Morrice N., Peggie M., Campbell D.G., Gaestel M., Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J. 2002, 21(23):6505-6514. Dec 2.
33. Rousseau S., Peggie M., Campbell D.G., Nebreda A.R., Cohen P. Nogo-B is a new physiological substrate for MAPKAP-K2. Biochem. J. 2005, 391(Pt 2):433-440. Oct 15.
34. Sandler H., Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem. Soc. Trans. 2008, 36(Pt 3):491-496. Jun.
35. Sousa A.M., Liu T., Guevara O., Stevens J., Fanburg B.L., Gaestel M., Toksoz D., Kayyali U.S. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGF-β are dependent upon MK2. J. Cell. Biochem. 2007, 100:1581-1592.
36. Streicher J.M., Ren S., Herschman H., Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ. Res. 2010, 106(8):1434-1443. Apr 30.
37. Thomas T., Timmer M., Cesnulevicius K., Hitti E., Kotlyarov A., Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J. Neurochem. 2008, 105(5):2039-2052. Jun.
38. Wamhoff B.R., Bowles D.K., Owens G.K. Excitation-transcription coupling in arterial smooth muscle. Circ. Res. 2006, 98(7):868-878. Apr 14.
39. Wang X., Xu L., Wang H., Young P.R., Gaestel M., Feuerstein G.Z. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J. Biol. Chem. 2002, 277(46):43968-43972. Nov 15.
40. Ward B., Seal B.L., Brophy C.M., Panitch A. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J. Pept. Sci. 2009, 15(10):668-674. Oct.
41. Ward B.C., Kavalukas S., Brugnano J., Barbul A., Panitch A. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J. Surg. Res. 2011, 169(1):e27-36. July 1.
42. Winzen R., Kracht M., Ritter B., Wilhelm A., Chen C.Y., Shyu A.B., Müller M., Gaestel M., Resch K., Holtmann H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 1999, 18(18):4969-4980. Sep 15.